

# PHAR-EAST

## ASIA'S PHARMA & BIOTECH FESTIVAL

**Innovation. Commercialisation. Access.**

(Previously known as the 12<sup>th</sup> BioPharma Asia Convention)

18-20 March 2019

Singapore

SPARK SOMETHING  
**TERRAPINN** 

## AGENDA AT A GLANCE

Preconference Day, 18 <sup>th</sup> March 2018 (Only for 3 day conference pass holder)				
<b>PHAR-EAST PHARMA 4.0 MEDIDATA WORKSHOP</b>				<b>PHAR-EAST BIOTECH BOOTCAMP</b>
<b>PHAR-EAST CLINICAL TRIALS WORKSHOP</b>	<b>PHAR-EAST CLINICAL TRIALS SITE TOUR</b>			
End of Pre-Conference Day				
Day 1, 19 <sup>th</sup> March 2019				
Keynote Opening				
Speed networking & Exhibition Visit				
<b>PHAR-EAST IMMUNOTHERAPY</b> <i>This track features Asia's progress in immunotherapy. Learn more about various discovery, development and production challenges in Asia, and explore how you can be part of this cutting-edge industry with knowledge exchange between the east and west.</i>	<b>PHAR-EAST CLINICAL TRIALS</b> <i>Excellence in clinical trials</i>	<b>PHAR-EAST MARKET ACCESS</b> <i>After getting regulatory approval for your drug, who pays? This one-day track, held back-to-back with Regulatory Affairs features formulas and pathways for reimbursement. Join us to discuss potential solutions to commercialisation challenges with industry peers.</i>	<b>PHAR-EAST PHARMA 4.0</b> <i>Look to the future in this exciting track, as we explore the most exciting and innovative disruptive technology drug discovery, development &amp; production. If you want to future-proof your business and identify exciting new trends, this is the track for you.</i>	<b>PHAR-EAST BIOTECH INVESTMENT</b> <i>If you want to discover the most innovative biotech companies in Asia, this is the track for you. Featuring biopharma biotech start-ups from across the region, join us here to learn more about their products, pipelines and pathway to commercialisation. You'll also hear from investors sharing more about what they look for in their portfolio companies.</i>
Going Global And Keeping It Local	Clinical Quality Assurance	Patient Access	Pharma 4.0: Drug Development	Can Asian biotech hubs compete globally?
Networking Luncheon and Exhibition Visit				
Immuno-Oncology in Asia	Clinical Design	Evidence Based Approach	Pharma 4.0: Digital Supply	Investor perspectives: Accessing capital for scaling up your biotech
Networking Refreshment				
Cancer Vaccines	Digital Trials	Value & Affordability	Pharma 4.0: Next-Generation Commercial Partnership Models	Leveraging larger capital pools: Let's talk listings & capital markets
Networking cocktail End of Day 1				
Day 2, 20 <sup>th</sup> March 2019				
Keynote Opening				
Roundtable discussion				
Morning Refreshment & Exhibition Visit				
<b>PHAR-EAST IMMUNOTHERAPY</b>	<b>PHAR-EAST CLINICAL TRIALS</b>	<b>PHAR-EAST REGULATORY AFFAIRS</b> <i>Join here to discuss solutions to commercialisation challenges from the regulatory perspective as we explore different regulatory pathways across Asia.</i>	<b>PHAR-EAST PHARMA 4.0</b>	<b>PHAR-EAST BIOTECH INVEST</b>
Targeted Therapies	Clinical Development	Regional Regulatory Partnership	Pharma 4.0: Data & Predictive Analytics	Attracting VC capital: What are investors looking for from Asian biotechs?
Networking Luncheon and Exhibition Visit				
Combination Therapies	Multi Regional Clinical Trials (MRCT)	Innovative New Drug Registration	Pharma 4.0 Digital Therapeutics	The Greater China Opportunity: Capital raising & partnerships
Immunotherapy Beyond Oncology	MRCT Adoption & Implications	Compliance	Pharma 4.0: Patient Centricity	Southeast Asia Focus: Fostering homegrown innovation and biotech firms
Close of Phar-East 2019				



## CONFERENCE ADVISORS



**Hardy Chan**  
Chairman & President of Allianz  
Pharmascience  
Co-founder and senior advisor of  
ScinoPharm, Taiwan



**Benjamin Seet**  
Executive Director  
Biomedical Research Council,  
A\*STAR, Singapore



**Carrie Hillyard**  
Chairman  
Fitgenes, Australia



**Joe Zhou**  
CEO  
Genor BioPharma, Walvax Group,  
China



**James Garner**  
CEO  
Kazia Therapeutics, Australia



**Alex Matter**  
CEO  
Experimental Therapeutics  
Centre & D3, A\*STAR, Singapore



**Dwo Yuan Sia**  
Chief Technology Officer  
BravoVax, China



**GS Reddy**  
Senior Vice President  
Brilliant Bio Pharma Pte Ltd  
India



**Stewart Geary**  
Senior Vice President, Chief  
Medical Officer and Director,  
Corporate Medical Affairs  
Eisai, Japan



**Crystal Sun**  
CEO Assistant & Director,  
Regulatory & Government Affairs,  
Fosun Kite Biotechnology, China



**Hui Hsing Ma**  
Senior Advisor  
TVM Capital Healthcare



**H.Fai Poon**  
President  
Quacell Biotech, China



**Vicky Han**  
Senior Director, Regulatory Policy  
Group Lead  
Janssen, J&J, Singapore



**Carl Firth**  
CEO & Founder  
ASLAN Pharma, Singapore




**James Cai**  
VP Global Regulatory Affairs  
Amgen JAPAC



**Josemund Menezes**  
Director, Medical Affairs &  
Clinical Development  
Tessa Therapeutics, Singapore



**I-Ning Tang**  
Team Leader, Center of  
Consultation  
Taiwan Center for Drug  
Evaluation



**Joseph Mocanu**  
Managing Director  
Verge Capital Management,  
Singapore



**Siew Hwa Ong**  
Chairman  
BioSingapore



**Shwen Gwee**  
General Manager, Digital  
Accelerator (Global Drug  
Development)  
Novartis



**Jeff Weisel**  
Life Sciences & Healthcare,  
Transaction Advisory, EY  
National Health Innovation  
Centre Evaluation Panel,  
Ministry of Health Singapore



**BinTean Teh**  
Deputy Director (Research),  
National Cancer Centre of  
Singapore  
Deputy Director (Scientific),  
SingHealth Duke-NUS Institute  
of Precision Medicine



**Stefan Glück**  
Vice President, Global Medical  
Affairs,  
Celgene, USA



## CONFIRMED SPEAKERS

### PHARMA & BIOTECH

1. **Jun Feng**, Market Access Associate Director - Oncology, JAPAC, **AbbVie, Singapore**
2. **Charles Stacey**, CEO, **Accera Pharma, Singapore**
3. **Judy Walker**, Chief Medical Officer, **Accera Pharma, Singapore**
4. **Ian Huen**, CEO, **Aptorum Group, Hong Kong, China**
5. **Carl Firth**, CEO, **ASLAN Pharma, Singapore**
6. **Harish Dave**, Chief Medical Officer, **AUM Biosciences, Singapore**
7. **Vishal Doshi**, CEO, **AUM Biosciences, Singapore**
8. **Arani Chatterjee**, Senior Vice President, Clinical Research, **Aurobindo, India**
9. **Vivian Bian**, COO, **BeiGene, China**
10. **Dwo Yuan Sia**, Chief Technology Officer, **BravoVax, China**
11. **Meng Chi Chen**, Director, Business Development, **BRIM Biotechnology, Taiwan**
12. **Seong-Choon Choe**, Head, Seoul Research Institute, **Boryung Pharmaceutical, South Korea**
13. **Nir Arbel**, Cofounder & CEO, **Carmentix, Singapore**
14. **Alexandre Civiére**, Project Manager, **Cell Prothera, Singapore**
15. **Frank Jiang**, CEO, **CStone, China**
16. **Stefan Glück**, Vice President, Global Medical Affairs, **Celgene, USA**
17. **David Benshoof Klein**, CEO and Founder, **Click Therapeutics, USA**
18. **Ed Rosen**, Co-Founder, **Elucida Oncology**, Executive in Residence, **Columbia Technology Ventures, USA**
19. **Pratapa S**, Former Senior Director, **Dr Reddy's Laboratories, India**
20. **Pei Yin Tan**, Director, Asia Clinical Operations, Medicine Development Center, **Eisai Clinical Research, Singapore**
21. **Jeonghoon Han**, Vice President Chief Development Officer and Chief Financial Officer, **Eutilex, South Korea**
22. **Carrie Hillyard**, Chairman, **Fitgenes, Australia**
23. **Crystal Sun**, Assistant CEO & Director, Regulatory & Government Affairs, **Fosun Kite Biotechnology, China**
24. **Sam Shen**, QA Director, **Fosun Kite Biotechnology Co.,Ltd., China**
25. **TS Balganes**, President, **Ganga Gen, India**
26. Senior representative, **Glenmark Pharmaceuticals**
27. **Maggie Lim**, Director, Clinical Quality Assurance, Pharma R&D, APAC, Global Quality Assurance, R&D Chief Regulatory Office, **GSK, Singapore**
28. **Maijing Liao**, Senior Vice President, Head of Business Development and Portfolio Management, **Harbour BioMed, China**
29. **Mario Bertazzoli**, Director, Group Head of Drug Safety, **Helsinn Healthcare, Switzerland**
30. **Piers Ingram**, CEO, **Hummingbird Biosciences, Singapore**
31. **Sabrina Ng**, Chief Financial Officer, **Hummingbird Biosciences, Singapore**
32. **Maria Chen**, Director, Business Development, **Immunwork, Taiwan**
33. **Wenzhi Tian**, MD, Chairman, CEO, **ImmuneOnco Biopharma, China**
34. **Nick Ede**, Chief Technology Officer, **Imugene, Australia**
35. **George Kopsidas**, Executive Director and Chief Scientific Officer, **Imunexus, Australia**
36. **Anil Pareek**, President, Medical Affairs and Clinical Research, **IPCA, India**
37. **Nathan Kothadaraman**, Director, Market Access and Government Affairs, **Janssen, Malaysia**
38. **James Garner**, CEO, **Kazia Therapeutics, Australia**
39. **Chongdeok Park**, Chief Development Officer, **Kolon Pharmaceuticals, South Korea**
40. **Kamal Amin**, Senior Clinical Supply Manager, **Fujifilm Kyowa Kirin Biologics, UK**
41. **Vicky Han**, Senior Director, Regulatory Policy Group Lead, **Janssen, J&J, Singapore**
42. **Prabhuram Krishnan**, South Asia Medical Director, **Ipsen Pharma, Singapore**
43. **Victor Li**, CEO, **LionTCR, Singapore**
44. **Antonio Bertoletti**, Co-Founder, **LionTCR, Singapore**
45. **Stephanie Liu**, Senior Clinical Quality Assurance Advisor, **Lundbeck, Singapore**
46. **Gopal Rao**, Global Business Development and Services Outsourcing, **Lupin, India**
47. **Antonio Lee**, Global Head of Business Development, **MEDIPOST, CEO& Managing Director, MEDIPOST AMERICA, South Korea**
48. **Jason Widjaja**, Associate Director, Global Data Science (AI & Data Products), **MSD, Singapore**
49. **Kum Cheun (KC) Wong**, Head of Asia Pacific, Regulatory and Development Policy, **Novartis, Singapore**
50. **Ogan Gurel**, Founder & CEO, **NovumWaves, South Korea**
51. **Shwen Gwee**, General Manager, Digital Accelerator (Global Drug Development), **Novartis, USA**
52. **Shweta Uppal**, Head, Clinical, Medical, Regulatory, Quality and Pharmacovigilance, **Novo Nordisk, Malaysia**
53. **Xichen Lin**, Research Director, Search & Evaluation, **Novo Nordisk, China**
54. **Anand Gautam**, Head of External Science & Innovation, **Pfizer, Australia**
55. **Handsome Ji**, APAC publishing lead, **Pfizer, China**
56. **Enver Erkan**, Country Manager, **Pfizer, Singapore**
57. **Yuliana Indriati**, President Director, **PT Kalbe Genexine, Indonesia**
58. **Hyejin Shin**, Director, Group Leader, Clinical QA, **Samsung Bioepis, South Korea**
59. **Shailendra Bajpai**, Global Head of Disease Management, **Sanofi, Singapore**
60. **Yong Ho Oh**, Regional Clinical Project Manager, ISS Project Manager, **Sanofi, Singapore**
61. **Byung-Geon (BG) Rhee**, CEO, **SCM Lifesciences**, Chairman, Council for Advanced Regenerative Medicine, Former President, **Green Cross Corporation, South Korea**
62. **Gloria Wang**, Chief Medical Officer, **Shanghai Sinobioway Sunterra Biotech, China**
63. **Liping Liu**, Founder, CEO& CSO, **ShenZhen HighTide Biopharmaceuticals, China**
64. **Raphael Aswin**, Vice President R&D and Regulatory, **SOHO Global Health, Indonesia**
65. **Philippe Pinton**, Regional Head, Specialty Therapy, **Takeda, Japan**
66. **Susanne Weissbacker**, Global Head of Access to Medicines, **Takeda, Singapore**
67. **Aung Myo**, Vice President, Clinical Development, **Tessa Therapeutics, Singapore**
68. **Josemund Menezes**, Director, Medical Affairs & Clinical Development, **Tessa Therapeutics, Singapore**
69. **Seok Joong Kim**, Board Member, Director and Head of Business Development, **Toolgen, South Korea**
70. **William Jia**, CSO, **Virogen Biotech, China**
71. **Joe Zhou**, CEO, Genor Biopharma, **Walvax Group, China**
72. **Robert Yu**, Senior Vice President, Operations, **Yuyu Pharma, South Korea**
73. **Billy Cho**, CFO, **Zai laboratories, China**

74. **Christian-Laurent Bonte**, Managing Director, **ARC Capital, Singapore**
75. **Gavin Teo**, General Partner, **B Capital, USA**
76. **Sean Cao**, Managing Director, **C-Bridge Capital Partners LLC, USA**
77. **Haolin Sung**, Director, Direct Investment Department, **Diamond BioFund, Taiwan**
78. **Sinclair Dunlop**, Managing Director, **Epidarex Capital, UK**
79. **Xiangqian (XQ) Lin**, Managing Partner, **Esco Ventures, Singapore**
80. **Ashish Patel**, Head of Research, Investment Manager, **Mercia Technologies PLC, UK**

## INVESTORS & BANKS


81. **Jeffry Wu**, Managing Director, **Milestone Capital, China**
82. **Hironoshin Nomura**, Senior Analyst, **Mizuho Securities, Japan**
83. **Alfred Scheidegger**, Partner & Founder, **Nextech Invest, Switzerland**
84. **Marietta Wu**, Managing Partner, **Quan Capital, China**
85. **Joseph Mocanu**, Managing Director, **Verge Capital Management, Singapore**

## OTHERS

86. **Sir David Lane**, Chief Scientist, **A\*STAR, Singapore**
87. **Mrunalini Jagtap**, Data Management Lead, **Singapore Institute for Clinical Sciences (SICS), A\*STAR, Singapore**
88. **Nathanael Faibis**, CEO, **Alodokter, Indonesia**
89. **Nitin Jain**, VP Asia Pacific, **Ancillare, Singapore**
90. **Raghu Bathina**, CEO, **Celes Care, Founder, Future World Studios, India**
91. **Lynne Baxter**, Lead Clinical Research Scientist, Precision Nutrition D-Lab, **Danone Nutricia Research, Singapore**
92. **Fiona Wong**, Team Leader Clinical Studies ASPAC, **Danone Nutricia Research, Singapore**
93. **Salah Uddin**, Assistant Director, **Directorate General of Drug Administration, Bangladesh**
94. **Reenita Das**, Partner, **Frost & Sullivan, USA**
95. **Mohd Fazli Shuib**, Head, Pharmacy Services, **FV Hospital, Vietnam**
96. **Sushant Sahastrabudhe**, Director, Enteric Fever, **International Vaccine Institute, South Korea**
97. **Sook Yee Yap**, Vice President, **Malaysia Rare Disease Society, Malaysia**
98. **Eunho Shin**, Head, Solution Consultant APeJ, **Medidata Solutions, South Korea**
99. **Aparajeeta Priyadarasini**, Solution Consultant, **Medidata Solutions, India**

100. **Phusit Prakongsai**, Acting Senior Advisor, Health Promotion, Office of Permanent Secretary, **Ministry of Public Health, Thailand**
101. **Nadia Suttikulpanich**, Head of Fuchsia Innovation Center, **Muang Thai Life Assurance, Thailand**
102. **Sophie Tsou**, Associate Investigator, Division of Biostatistic and Bioinformatics, Institute of Population Health Sciences, **National Health Research Institute, Taiwan**
103. **Mayank Gurnani**, Associate Professor, Industry Liaison Office, **National University of Singapore, Singapore**
104. **Teck Jack Tan**, Chairman & Medical Director, **Northeast Medical Group, Singapore**
105. **Henry Ines**, CEO, **Project Shivom, USA**
106. **JingPing Yeo**, Director, Research Integrity, Compliance, Ethics, **Singapore Health Services, Singapore**
107. **Poh Loong Soong**, Founder & CEO, **Ternion Biosciences, Singapore**
108. **I-Ning Tang**, Team Leader, Center of Consultation, **Taiwan Center for Drug Evaluation, Taiwan**
109. **Donna Collett**, Managing Partner, **Valeur Consulting, Australia**
110. **Edmund Lim**, Co-Founder and President, **WeCareJourney, Malaysia**

PRE- CONFERENCE  
DAY 0  
18<sup>th</sup> MARCH 2019

Preconference Day, 18 <sup>th</sup> March 2018 (Only for 3 day conference pass holder, attendee is allowed to choose between a combination of 1 morning+1 afternoon workshop, or a full day site tour)			
<p style="text-align: center;"><b>PHAR-EAST</b> <b>CLINICAL TRIALS &amp; PHARMA 4.0</b> <b>HARNESS THE POWER OF DATA FOR SMARTER DRUG DEVELOPMENT</b> (By Invitation only) <b>08:30-12:00</b></p> <p>08:30-9:00 - Registration 09:00-9:30 - Welcome and Introduction 09:30-10:00 - Globalization trends and patient centricity approach in clinical trials 10:00-10:30 - Improve site satisfaction, optimize trial design and monitoring process with Predictive Analytics, Machine Learning and Artificial Intelligence 10:30-11:00 - Break 11:00-11:30 - Adaptive design clinical trials - best practice and challenges involved 11:30-12:00 - Closing and Networking</p> <p><u>Sponsored by:</u></p>  <p><b>Workshop leaders:</b> Eunho Shin, Head, Solution Consultant APeJ, Medidata Solutions Aparajeeta Priyadarasini, Solution Consultant, Medidata Solutions</p>	<p style="text-align: center;"><b>PHAR-EAST</b> <b>SITE TOUR</b></p> <p>This full day site tour allows up to 30 international attendees to witness Singapore R&amp;D facilities and clinical sites. Priority is given to 3 day pass international attendee on first-come-first-serve basis.</p> <p>Agenda (subject to changes) 08:30-09:00 Report at Biopolis, Nanos building 09:00-10:00 Tour first A*STAR stop: ETC 10:00-10:15 Walk over to Helios building 10:15-11:15 Tour second A*STAR stop: SBIC 11:15-11:30 Walk over to Neuros&amp; Immunos building 11:30-12:30 Tour third A*STAR stop: IMB 12:30-14:00 Lunch at Biopolis 14:00-14:15 Report at Genome building 14:15-15:15 Tour fourth A*STAR stop: GIS, Genome building 15:15-15:45 Travel to Trial site (Details to be confirmed) 15:45-16:45 Clinical trial site tour 17:00 End of site tour</p> <p><b>About ETC:</b> The Experimental Therapeutics Centre (ETC) was set up in 2006 as a centre of excellence to advance and accelerate drug discovery in Singapore. Its primary mission is to guide early stage scientific discoveries towards proof-of-concept in man and translate scientific discoveries into diagnostics and research tools in order to serve unmet medical needs. For more information, please visit <a href="https://www.a-star.edu.sg/etc/">https://www.a-star.edu.sg/etc/</a></p> <p><b>About SBIC:</b> The Singapore Bioimaging Consortium (SBIC) is one of the 10 research institutes of the Biomedical Research Council under the A*STAR. SBIC is a leading preclinical bio-imaging platform in Asia located at biopolis Helios building. For more information, please visit <a href="https://www.a-star.edu.sg/sbic/">https://www.a-star.edu.sg/sbic/</a></p> <p><b>About IMB:</b> As the newest institute of the A*STAR biomedical sciences cluster, Institute of Medical Biology (IMB) focusses its research portfolio on the critical and challenging interface between basic science and medicine. Its goal is to understand mechanisms underlying human disease, to discover new and effective approaches to combating illness and promoting wellbeing. For more information, please visit <a href="https://www.a-star.edu.sg/imb/">https://www.a-star.edu.sg/imb/</a></p> <p><b>About GIS:</b> The Genome Institute of Singapore (GIS) is the national flagship programme for the genomic sciences in Singapore. It was established in June 2000, and initially known as the Singapore Genomics Programme. GIS houses over 300 scientists, trainees and staff. The major technical platforms of high throughput sequencing, molecular cytogenetics, bioinformatics, single cell genomics, high throughput/ content screening and genome engineering have been integrated with programmes in molecular and cellular biology, computational biology and human genetics. For more information, please visit: <a href="https://www.a-star.edu.sg/gis/">https://www.a-star.edu.sg/gis/</a></p>	<p style="text-align: center;"><b>PHAR-EAST</b> <b>BIOTECH BOOTCAMP Part 1</b> <b>PITCHING WORKSHOP</b> (Details to be announced)</p> <p><b>Workshop leader:</b> Carrie Hillyard, Chairman, Fitgenes, Australia Craig Dixon, Founder, Accelerating Asia, Singapore*</p>	<p style="text-align: center;"><b>PHAR-EAST</b> <b>PHARMA 4.0 WORKSHOP</b> <b>BLOCKCHAIN IN BIOPHARMA</b> (Details to be announced)</p> <p><b>Workshop leader:</b> Ogan Gurel, Founder &amp; CEO, NovumWaves, South Korea</p>
<p style="text-align: center;"><b>PHAR-EAST</b> <b>CLINICAL TRIALS</b> <b>CLINICAL TRIAL AND ISSUES MANAGEMENT – SKILLS FOR EFFECTIVE SOLUTIONS</b> <b>14:00-17:30</b></p> <p>Project management skill is crucial in large scale, cross country studies. Whether you are from a sponsor company, or a CRO operating in Asia, it is essential learning from experts on skills for effective problem identification and solving. Coming from both provider and industry perspective Maggie Lim, Director, Clinical Quality Assurance of Pharma R&amp;D, Asia-Pacific of GSK will share her 17 years' experience in clinical research and trials management with you at this 2.5 hours workshop.</p> <p>Key topics to be covered in this workshop include:</p> <ul style="list-style-type: none"> <li>Identifying root causes (Root Cause Analysis (RCA))</li> <li>workout of Corrective &amp; Preventive Measures (CAPA)</li> <li>Measuring their effectiveness</li> </ul> <p><b>Workshop leader:</b> Maggie Lim, Director, Clinical Quality Assurance, Pharma R&amp;D, APAC, Global Quality Assurance, R&amp;D Chief Regulatory Office, GSK, Singapore</p>	<p style="text-align: center;"><b>PHAR-EAST</b> <b>BIOTECH BOOTCAMP Part 2</b> <b>BUILDING A SUCCESSFUL CASE IN PHARMA-ON BUSINESS, BRANDS, AND PEOPLE</b> <b>14:00-17:30</b></p> <p>Preparing for a business case and presenting to an immediate superior, headquarters, investors, or client is a regular activity for the busy pharma executive. How do you make sure that you have performed an adequate stakeholder analysis and built up a simplified yet professional case for your local or international target in ensuring the highest chance of success? Join Donna Collett, a pharma veteran turned consultant who has over 20 years' experience in pharmaceutical marketing, sales, people and product management, to find out the most effective way to communicate your business idea and effectively allow you to reach your business goals.</p> <p><b>Workshop leader:</b> Donna Collett, Managing Partner, Valeur Consulting, Australia</p>	<p style="text-align: center;"><b>PHAR-EAST</b> <b>PHARMA 4.0 WORKSHOP</b> (Details to be announced)</p>	<p style="text-align: center;"><b>PHAR-EAST</b> <b>PHARMA 4.0 WORKSHOP</b> (Details to be announced)</p>
End of Pre-Conference Day			

**MAIN CONFERENCE**  
**DAY 1**  
**19<sup>th</sup> MARCH 2019**

08:45	Organiser's welcome Remarks					
08:50	Chair's opening Remarks Joe Zhou, CEO, Genor Biopharma, Walvax Group, China					
<b>OPENING KEYNOTE PLENARY</b>						
09:00	<b>Going global and keeping it local: Is biotech innovation sustainable in Asia?</b> In this keynote presentation, Sir David Lane, one of the key scientists credited on the discovery of cancer gene p53, a gene which mutation cause near 50% of all human cancer, will share his view on how biomedical sciences have developed in Singapore, Japan and the remaining APAC region, and prospects for Asian biotech and pharma industry. <b>Sir David Lane, Chief Scientist, A*STAR, Singapore</b>					
09:20	<b>Looking east: Integrating Asia into the global era of innovative medicine</b> With the recent economic spurs and the widening of Asia's middle income population, many pharma returnees are building companies in their home countries to develop innovative drugs for the local population. No longer depending heavily on western R&D or imported patent expired generics & biologics drugs, innovative therapies created to treat Asia-prevalent diseases have started to become the new norm in the region. In this presentation, Dr BG Rhee, CEO of SCM Lifesciences, Chairman of Council for Advanced Regenerative Medicine and former president of Green Cross Corporation, the largest plasma protein manufacturer in Asia, will share with you his insights on these changes and what it means to both big international players and domestic companies. <b>Byung-Geon (BG) Rhee, CEO, SCM Lifesciences, Chairman, Council for Advanced Regenerative Medicine, Former President, Green Cross Corporation, South Korea</b>					
09:40	<b>KEYNOTE PANEL: Pharma 4.0: Women health &amp; Femtech as the next focus</b> Women's health goes beyond mother & childcare. For instance, women has a higher risk of cardiovascular diseases compared to men, hence there is a need to invest more on addressing the biological differences in mainstream disease studies to ensure a more effective, personalised treatment. In addition, big data & AI application on female subjects may also differ from male subjects, prompting a need to investigate how studies should be developed differently in the future. This panel brings experts to debate and discuss how femtech is shaping to be the next global pharma focus and the new areas of focus in women's healthcare.  Moderator: <b>Reenita Das, Partner, Frost &amp;Sullivan, USA</b>					
10:20	<b>Speed networking &amp; Networking Refreshment</b>					
	<b>PHAR-EAST IMMUNOTHERAPY</b>	<b>PHAR-EAST CLINICAL TRIALS</b>	<b>PHAR-EAST ACCESS</b>	<b>PHAR-EAST PHARMA 4.0</b>	<b>PHAR-EAST BIOTECH INVEST</b>	
	<b>GOING GLOBAL AND KEEPING IT LOCAL</b>	<b>CLINICAL QUALITY ASSURANCE</b>	<b>PATIENT ACCESS</b>	<b>PHARMA 4.0: DRUG DEVELOPMENT</b>		
11:15	Chair's opening remarks <b>Frank Jiang, CEO, CStone, China</b>	Chair's opening remarks <b>Anil Pareek, President, Medical Affairs and Clinical Research, IPCA, India</b>	Chair's opening remarks	Chair's opening remarks <b>James Garner, CEO, Kazia Therapeutics, Australia</b>	11:15	Chair's opening remarks <b>Carrie Hillyard, Chairman, Fitgenes, Australia</b>
11:20	<b>What's next after PD-L1? (topic to be confirmed)</b> <b>Aung Myo, Vice President, Clinical Development, Tessa Therapeutics, Singapore</b>	<b>A provider's perspective in ensuring clinical trial quality</b> <ul style="list-style-type: none"> <li>Suggestions in promoting collaboration required between pharma, CRO and providers to promote trial efficiency</li> <li>Educational efforts and processes preparation required to ensure trials quality</li> <li>Case study sharing</li> </ul> <b>JingPing Yeo, Director, Research Integrity, Compliance, Ethics, Singapore Health Services, Singapore</b>	<b>Starting from clinical phase: Patients involvement in building evidence and drug development (topic to be confirmed)</b> <b>Edmund Lim, Co-Founder and President, WeCareJourney, Malaysia</b>	<b>The transformation of the Bio pharma industry. Top growth opportunities for 2025</b> <b>Reenita Das, Partner, Frost &amp;Sullivan, USA</b>	11:20	<b>PANEL: Medtech, Diagnostics, Wearables- What are the next trends in biotech investment landscape?</b> Moderator: <ul style="list-style-type: none"> <li><b>Joseph Mocanu, Managing Director, Verge Capital Management, Singapore</b></li> </ul> Panellists: <ul style="list-style-type: none"> <li><b>Ashish Patel, Head of Research, Investment Manager, Mercia Technologies PLC, UK</b></li> </ul>



11:40	How do domestic companies gain edge in the competitive global immunotherapy landscape? Jeonghoon Han, Vice President Chief Development Officer and Chief Financial Officer, Eutilex, South Korea	Personalised risk assessment in clinical management <ul style="list-style-type: none"> <li>Disease management and specific screening for better risk assessment</li> <li>Targeted screening and clinical management of specific disease profile</li> <li>Product strategy and clinical development plan in establishing oncology pipelines</li> </ul> Seong-Choon Choe, Head, Seoul Research Institute, Boryung Pharmaceutical, South Korea	The role of industry in facilitating low to mid income countries to build capabilities and healthcare accessibility (Topic to be confirmed) Nathan Kothadaraman, Director, Market Access and Government Affairs, Janssen, Malaysia	Increasing transparency and knowledge-sharing efficiency with blockchain Henry Ines, CEO, Project Shivom, USA	<ul style="list-style-type: none"> <li>Richard Leaver, Partner, Boundary Capital Partners, UK*</li> <li>Simon Haworth, CEO&amp; Founder, Dynasty Biotech and the Sino-UK Fund, UK*</li> </ul>
	12:00	The next big trend in Asia immunotherapy landscape: A case study in China Frank Jiang, CEO, CStone, China	New considerations in ensuring trials efficiency and transparency This presentation shares insights from Asia, EMA and FDA inspections with case studies on biosimilar trials. It will also discuss the influence of the nature of company on site monitoring activities Hyejin Shin, Director, Group Leader, Clinical QA, Samsung Bioepis, South Korea	<b>PANEL:</b> Collaborative efforts in building the common ground for better accessibility and treatment <ul style="list-style-type: none"> <li>Key actions to bridge the gaps between stakeholders to provide for population in need</li> <li>Models in helping advocacy group to coordinate for better access to treatment</li> <li>Building the common ground in promoting better collaboration between advocacy groups, government, pharma and other stakeholders</li> </ul> Sook Yee Yap, Vice President, Malaysia Rare Disease Society, Malaysia Nadia Suttikulpanich, Head of Fuchsia Innovation Center, Muang Thai Life Assurance, Thailand Pratapa S, Former Senior Director, Dr Reddy's Laboratories, India Enver Erkan, Country Manager, Pfizer, Singapore Harjinder Singh Kandra, Director of Medical Affairs Capabilities, Merck Research Labs, India*	AI- enhanced drug development platforms Gavin Teo, General Partner, B Capital, Board member, Atomwise, USA
12:20	Development of cell therapy product for pediatric orphan disease - challenges and rewards <ul style="list-style-type: none"> <li>Case study on current and upcoming immunotherapy and stem cell products, i.e. Cartistem, Pneumostem (orphan indication for premature babies)</li> <li>Discussion on strategies in making immunotherapy and stem cell products more accessible for population in Asia, future plans and what's next beyond Asia?</li> </ul> Antonio Lee, Global Head of Business Development, MEDIPOST, CEO& Managing Director, MEDIPOST AMERICA, South Korea	Case study on regional differences in clinical audit and inspection (topic to be finalised) Stephanie Liu, Senior Clinical Quality Assurance Advisor, Lundbeck, Singapore	<b>PANEL:</b> Collaborative efforts in building the common ground for better accessibility and treatment <ul style="list-style-type: none"> <li>Key actions to bridge the gaps between stakeholders to provide for population in need</li> <li>Models in helping advocacy group to coordinate for better access to treatment</li> <li>Building the common ground in promoting better collaboration between advocacy groups, government, pharma and other stakeholders</li> </ul> Sook Yee Yap, Vice President, Malaysia Rare Disease Society, Malaysia Nadia Suttikulpanich, Head of Fuchsia Innovation Center, Muang Thai Life Assurance, Thailand Pratapa S, Former Senior Director, Dr Reddy's Laboratories, India Enver Erkan, Country Manager, Pfizer, Singapore Harjinder Singh Kandra, Director of Medical Affairs Capabilities, Merck Research Labs, India*	Innovative strategies to cope with the rise of superbugs Using innovative phage, combination, adjunct therapies in developing next generation antibiotics. TS Balganes, President, Ganga Gen, India*	12:20 Biotech Pitch Poh Loong Soong, CEO& Founder, Ternion Biosciences, Singapore
				12:30 Biotech Pitch Reserved for Korea Health Industry Development Institute (KHIDI)	
				12:40 Biotech Pitch Reserved for National Health Technology Park (NHTP), China	
12:40				12:40 R&D Management: Additional value enhancement through innovation Raphael Aswin, Vice President R&D and Regulatory, SOHO Global Health, Indonesia	12:50 Biotech Pitch Vishal Doshi, CEO, AUM Biosciences, Singapore
				13:00 Biotech Pitch Reserved for Korea Health Industry Development Institute (KHIDI)	
12:40	Exhibition Visit & Networking Lunch				13:10 Exhibition Visit & Networking Lunch
	IMMUNO-ONCOLOGY (I-O) IN ASIA	CLINICAL DESIGN	EVIDENCE BASED APPROACH	PHARMA 4.0: DIGITAL SUPPLY	14:10 <b>PANEL:</b> Investor perspectives: Accessing capital for scaling up your biotech Moderator: <ul style="list-style-type: none"> <li>Henry Ines, CEO, Project Shivom, USA</li> </ul>
14:10	Chair's opening remarks Josemund Menezes, Director, Medical Affairs & Clinical Development, Tessa Therapeutics, Singapore	Chair's opening remarks Anil Pareek, President, Medical Affairs and Clinical Research, IPCA, India	Chair's opening remarks	Chair's opening remarks	



14:20	<b>Big pharma perspectives: Using global pipeline development to serve Asia's population</b> Stefan Glück, Vice President, Global Medical Affairs, Celgene, USA	<b>Clinical research as tools in driving innovation</b> Anil Pareek, President, Medical Affairs and Clinical Research, IPCA, India	<b>Maximizing RWE and Patient Reported Outcomes in Regulatory &amp; reimbursement processes</b> Philippe Pinton, Regional Head, Specialty Therapy, Takeda, Japan	<b>Building an in-house pharma AI product team: Key steps &amp; considerations</b> <ul style="list-style-type: none"> <li>In-house vs outsource: What are the key benefits &amp; challenges in building in-house data science projects</li> <li>Ethics in consideration: How to make AI products more neutral and non-discriminative</li> </ul> Jason Widjaja, Associate Director, Global Data Science (AI & Data Products), MSD, Singapore		Panellists: <ul style="list-style-type: none"> <li>Haolin Sung, Director, Direct Investment Department, Diamond BioFund, Taiwan</li> <li>Chongdeok Park, Chief Development Officer, Kolon Pharmaceuticals, South Korea</li> </ul>
14:40	<b>Innovative therapeutics in immuno-oncology and inflammatory diseases</b> Maijing Liao, Co-Founder, Senior Vice President, Head of Business Development and Portfolio Management, Harbour BioMed, China	<b>Improving clinical trials with better stakeholder management</b> Yong Ho Oh, Regional Clinical Project Manager, ISS Project Manager, Sanofi, Singapore	<b>Making a value-outcome-based reimbursement model possible: How do we get there?</b> Jun Feng, Market Access Associate Director - Oncology, JAPAC, AbbVie, Singapore	<b>Clearer ROI &amp; minimum wastage: Clinical trial supply simulation software</b> <i>Reserved for CRO sponsor</i>	14:45	<b>Biotech Pitch</b> <i>Reserved for National Health Technology Park (NHTP), China</i>
15:00	<b>Platform technology for immuno-oncology product development, a case study</b> George Kopsidas, Executive Director and Chief Scientific Officer, Immunexus, Australia	<b>Biostatistics perspective in cross country clinical design</b> Sophie Tsou, Associate Investigator, Division of Biostatistic and Bioinformatics, Institute of Population Health Sciences, National Health Research Institute	<b>PANEL: RWE as the basis of value-based reimbursement: Applications in APAC's pharma industry</b> <ul style="list-style-type: none"> <li>Overview of data-driven reimbursement process in APAC</li> <li>Overcoming barriers to increase use of real world data</li> <li>Improving quality of real world data</li> <li>Standardising access and quality of RWE analytics</li> <li>Working with payors and regulators on possible value based reimbursement model for innovative drugs and beyond</li> </ul> Moderator: Joseph Mocanu, Managing Director, Verge Capital Management, Singapore Panellist(s): Gavin Teo, General Partner, B Capital, USA Jun Feng, Market Access Associate Director - Oncology, JAPAC, AbbVie, Singapore Evelyn Pang, Head of Operations, Sanofi Pasteur, Singapore*	<b>Reshaping your supply chain to address supply shortage: A patient-centric approach</b> Kamal Amin, Senior Clinical Supply Manager, Fujifilm Kyowa Kirin Biologics, UK	14:55	<b>Biotech Pitch</b> <i>Reserved for Korea Health Industry Development Institute (KHIDI)</i>
					15:05	<b>Biotech Pitch</b> Alexandre Civiére, Project Manager, Cell Prothera, Singapore
15:20	<b>Immunotherapy in clinical practices: Opportunities and key challenges</b> (Topic to be confirmed) Piers Ingram, CEO, Hummingbird Biosciences, Singapore	<b>Paediatric subject recruitment: A cross industry case study &amp; future trend</b> Fiona Wong, Team Leader Clinical Studies ASPAC, Danone Nutricia Research, Singapore	Moderator: Joseph Mocanu, Managing Director, Verge Capital Management, Singapore Panellist(s): Gavin Teo, General Partner, B Capital, USA Jun Feng, Market Access Associate Director - Oncology, JAPAC, AbbVie, Singapore Evelyn Pang, Head of Operations, Sanofi Pasteur, Singapore*	<b>FIRESIDE CHAT: From data to drug: Improving your supply chain with emerging technology</b> (To be confirmed) Kamal Amin, Senior Clinical Supply Manager, Fujifilm Kyowa Kirin Biologics, UK Nitin Jain, VP Asia Pacific, Ancillare, Singapore	15:15	<b>Biotech Pitch</b> <i>Reserved for Korea Health Industry Development Institute (KHIDI)</i>
					15:25	<b>Biotech Pitch</b> Sabrina Ng, Chief Financial Officer, Hummingbird Biosciences, Singapore
					15:35	<b>Biotech Pitch</b> Liping Liu, Founder, CEO& CSO, ShenZhen HighTide Biopharmaceuticals, China
15:40	Exhibition Visit & Networking Refreshments				15:45	<b>Exhibition Visit &amp; Networking Refreshments</b>
	<b>CANCER VACCINES</b>	<b>DIGITAL TRIALS</b>	<b>VALUE &amp; AFFORDABILITY</b>	<b>PHARMA 4.0: NEXT GENERATION COMMERCIAL PARTNERSHIP MODELS</b>	16:05	<b>PANEL: Leveraging larger capital pools: Let's talk listings &amp; capital markets</b> <ul style="list-style-type: none"> <li>Global capital markets and opportunities</li> <li>Biotech market readiness in APAC public listing</li> </ul>
16:30	Chair's Opening Remarks	Chair's Opening Remarks Anil Pareek, President, Medical Affairs and Clinical Research, IPCA, India	Chair's Opening Remarks	Chair's Opening Remarks		

16:40	<b>Beyond prevention: Latest cancer vaccine developments in Asia</b> Dwo Yuan Sia, Chief Technology Officer, BravoVax, China	<b>Leveraging digital platforms and Electronic Medical Record (EMR) to improve patient experience and clinical trials subject recruitment</b> Mohd Fazli Shuib, Head, Pharmacy Services, FV Hospital, Vietnam	<b>Sustainable patient access model to oncology &amp; innovative medicines: A case study</b> Susanne Weissbacker, Global Head of Access to Medicines, Takeda, Singapore	<b>Scaling new heights: Fast-tracking success in Asia with open innovation and new partnership opportunities</b> Robert Yu, Senior Vice President, Operations, Yuyu Pharma, South Korea	<ul style="list-style-type: none"> <li>Hong Kong- the next Asia biotech capital destination?</li> </ul> Panellist(s): <ul style="list-style-type: none"> <li>Carl Firth, CEO, ASLAN Pharma, Singapore</li> <li>Hironoshin Nomura, Senior Analyst, Mizuho Securities, Japan</li> <li>Christian-Laurent Bonte, Managing Director, ARC Capital, Singapore</li> <li>Billy Cho, CFO, Zai laboratories, China</li> </ul>
					16:40 <b>Biotech Pitch</b> <i>Reserved for Korea Health Industry Development Institute (KHIDI)</i>
17:00	<b>Gastric and breast cancer vaccines: Case study and latest findings</b> Nick Ede, Chief Technology Officer, Imugene, Australia	<b>Innovating clinical trials with digital platforms: A cross industry case study</b> Lynne Baxter, Lead Clinical Research Scientist, Precision Nutrition D-Lab, Danone Nutricia Research, Singapore	<b>Cost management &amp; innovative pricing strategies in high value disease management (topic to be confirmed)</b> Shailendra Bajpai, Global Head of Disease Management, Sanofi, Singapore	<b>Partnering through acquisition: How new M&amp;A trends in Asia are fostering innovation</b> Joe Zhou, CEO, Genor Biopharma, Walvax Group, China	16:50 <b>Biotech Pitch</b> William Jia, CSO, Virogen Biotech, China
					17:00 <b>Biotech Pitch</b> <i>Reserved for National Health Technology Park (NHTP), China</i>
					17:10 <b>Biotech Pitch</b> Maria Chen, Director, Business Development, Immunwork, Taiwan
17:20	<b>Next Generation Therapeutic Cancer Vaccines Affordable to the Masses</b> Michael Har-Noy, CEO, Immunovative Therapies, Israel *	<b>Medtech? AI? Big Data? What's next in enabling more personalised patient care</b> <i>Reserved for CRO sponsor</i>	<b>Technology transfer and Product Development Partnerships (PDPs) in making vaccines affordable</b> Sushant Sahastrabuddhe, Director, Enteric Fever, International Vaccine Institute, South Korea	<b>Breaking the boundary of traditional B2B partnership: Next generation pharma-PE/VC model</b> Gopal Rao, Global Business Development and Services Outsourcing, Lupin, India	17:20 <b>Biotech Pitch</b> Meng Chi Chen, Director, Business Development, BRIM Biotechnology, Taiwan
					17:30 <b>Biotech Pitch</b> <i>Reserved for National Health Technology Park (NHTP), China</i>
17:40	<b>Neoantigen cancer vaccine- the new dawn in immuno-oncology</b> Yong Qian, CEO & Founder, Biomedicure, China*				17:40 <b>Biotech Pitch</b> Nir Arbel, Cofounder & CEO, Carmentix, Singapore
17:50					17:50 <b>Biotech Pitch</b> Billy Cho, CFO, Zai laboratories, China
18:00	Networking Cocktail & End of Conference Day 1				

DAY 2  
 20<sup>th</sup> MARCH 2019

08:45	Organiser's welcome Remarks	
08:50	Chairman's opening Remarks	
	<b>OPENING KEYNOTE PLENARY</b>	
09:00	<p><b>Disrupt before being disrupted: Using digital tech to connect to previously uneconomic chronic disease customers</b>          Insurance is a tricky part of healthcare business. Increased healthcare costs lead to a higher profit for pharma and provider companies, but burdens the government budget and hurts the insurance business. Since taking care of a chronic patient is a lifelong commitment, the availability of insurance to cover this essential treatment is often expensive and uneconomical. Join Nadia Suttikulpanich, Head of the Fuchsia Innovation Center, part of Muang Thai Life Assurance, Thailand as she shares how they are adopting digital tech to pilot chronic disease cover to provide for patients in need while keeping their insurance business profitable.  <b>Nadia Suttikulpanich, Head of Fuchsia Innovation Center, Muang Thai Life Assurance, Thailand</b></p>	
09:20	<p><b>The path to personalised medicine: Key developments</b>          Everyone knows the potential benefits of personalised medicine, but how do we get there? Finding and better defining disease through biomarkers and more accurate diagnostics. Targeted therapeutics to leverage new and emerging diagnostic capabilities. Personalized Medicine to Real-Time Medicine. How to drive success across industry and clinical implementation in an economic manner. This presentation discusses various strategies and key considerations to drive the symbiosis between academia, industry and clinical medicine to drive vastly improved patient outcomes.  <b>Ed Rosen, Co-Founder, Elucida Oncology, Executive in Residence, Columbia Technology Ventures, USA</b></p>	
09:40	<p><b>KEYNOTE PANEL: Pharma 4.0: Digital disruption-New players, new opportunities</b>          Disruptive technology is transforming industries across the globe, and pharma is no exception. With a focus on innovation and a growing reputation for excellence in cutting-edge R&amp;D, Asia's pharma and biotech industry is evolving. Look to the future in this exciting panel, as we explore the most exciting and innovative disruptive technology in drug discovery, development and patient engagement. If you want to future-proof your business and identify exciting new trends, this is the right session for you.</p> <p>Moderator:  <b>Shwen Gwee, General Manager, Digital Accelerator (Global Drug Development), Novartis, USA</b></p> <p>Panellist(s):  <b>Teck Jack Tan, Chairman &amp; Medical Director, Northeast Medical Group, Singapore</b>  <b>Raghu Bathina, CEO, Celes Care, Founder, Future World Studios, India</b>  <b>David Benshoof Klein, CEO and Founder, Click Therapeutics, USA</b>  <b>Uday Saxena, Chief Scientific Officer, Dr Reddy's Laboratories, USA*</b></p>	
10:20	<b>Roundtable discussion</b>	<b>PHAR-EAST BIOTECH INVEST</b>
	<p><b>Table 1</b> Working with clinical outsourcing partners: Risk management and prevention  <b>Pei Yin Tan, Director, Asia Clinical Operations, Medicine Development Center, Eisai Clinical Research, Singapore</b></p> <p><b>Table 2</b> Fostering commercial partnerships to tap on emerging APAC markets  <b>Charles Stacey, CEO, Accera Pharma, Singapore</b></p> <p><b>Table 3</b> Regulatory collaboration and opportunities in more efficient drug development  <b>Phusit Prakongsai, Acting Senior Advisor, Health Promotion, Office of Permanent Secretary, Ministry of Public Health, Thailand</b></p> <p><b>Table 4</b> Strategies in making drugs more affordable and accessible to patients in developing countries  <b>Pratapa S, Former Senior Director, Dr Reddy's Laboratories, India</b></p> <p><b>Table 5</b> Oncolytic viruses &amp; Microbiome- What's next in immunotherapy?</p> <p><b>Table 6</b> A convergent approach: Tapping on western expertise to serve Asia population  <b>Philippe Pinton, Regional Head, Specialty Therapy, Takeda, Japan</b></p> <p><b>Table 7</b> Precision to personalised medicine- How do we get there?  <b>Mrunalini Jagtap, Data Management Lead, Singapore Institute for Clinical Sciences (SICS), A*STAR, Singapore</b></p> <p><b>Table 8</b> Leveraging blockchain technology in making clinical trials more transparent and efficient</p> <p><b>Table 9:</b> Data Science in practice: How can sales reps and MSLs use Big Data?</p>	<p>10:20 <b>PANEL: Attracting VC capital: What are investors looking for from early stage Asian biotechs?</b>  <b>Moderator:</b>  <b>Mayank Gurnani, Associate Professor, Industry Liaison Office, National University of Singapore, Singapore</b>  <b>Panellist(s):</b></p> <ul style="list-style-type: none"> <li>• <b>Sinclair Dunlop, Managing Director, Epidarex Capital, UK</b></li> <li>• <b>Carrie Hillyard, Chairman, Fitgenes, Australia</b></li> <li>• <b>Alfred Scheidegger, Partner&amp; Founder, Nextech Invest, Switzerland</b></li> </ul>



	<p>Prabhuram Krishnan, South Asia Medical Director, Ipsen Pharma, Singapore  <b>Table 10:</b> The Singapore biotech ecosystem – What comes after the Inflexion?                  Senior representative, <a href="#">A*STAR, Singapore</a> *                  Senior representative, <a href="#">BioSingapore</a>*                  Senior representative, <a href="#">Enterprise Singapore</a>*</p>					
11:00	Exhibition Visit & Networking Refreshments				11:00	<p><b>Biotech Pitch</b>                  Reserved for Korea Health Industry Development Institute (KHIDI)</p>
	<p>PHAR-EAST  <b>IMMUNOTHERAPY</b></p>	<p>PHAR-EAST  <b>CLINICAL TRIALS</b></p>	<p>PHAR-EAST  <b>REGULATORY AFFAIRS</b></p>	<p>PHAR-EAST  <b>PHARMA 4.0</b></p>	11:10	<p><b>Biotech Pitch</b>                  Reserved for National Health Technology Park (NHTP), China</p>
	TARGETTED THERAPIES	CLINICAL DEVELOPMENT	REGIONAL REGULATORY PARTNERSHIP	PHARMA 4.0: DATA & PREDICTIVE ANALYTICS		
11:35	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks	11:20	<p><b>Biotech Pitch</b>                  Reserved for Korea Health Industry Development Institute (KHIDI)</p>
11:40	<p><b>Overview: Targeted therapies in enabling precision medicine</b></p> <ul style="list-style-type: none"> <li>Combination studies in Asia-latest updates</li> <li>Deciding between targeted oncology therapies vs I-O, key considerations</li> <li>Key actions transitioning from followers to leaders in targeted therapies</li> </ul> <p>Moderator:                  Harish Dave, Chief Medical Officer, AUM Biosciences, Singapore</p> <p>Panellist(s):  <a href="#">Vivian Bian</a>, COO, <a href="#">BeiGene</a>, China*</p>	<p>East meets west, the quest to cure                  Liping Liu, Founder, CEO&amp; CSO, ShenZhen HighTide Biopharmaceuticals, China</p>	<p>Convergence, harmonisation and collaboration: The evolution of Asia's pharma regulatory landscape                  Vicky Han, Senior Director, Regulatory Policy Group Lead, Janssen, J&amp;J, Singapore</p>	<p>Role of big data and bioinformatics in precision medicine  <a href="#">Ogan Gurel</a>, Founder &amp; CEO, <a href="#">NovumWaves</a>, South Korea*</p>	11:30	<p><b>Biotech Pitch</b>                  Reserved for National Health Technology Park (NHTP), China</p>
					11:40	<p><b>Biotech Pitch</b>                  Reserved for Korea Health Industry Development Institute (KHIDI)</p>
12:00	Moderator: Harish Dave, Chief Medical Officer, AUM Biosciences, Singapore	<p>Clinical Development of CAR-T, Stem Cells and other Cellular Therapy Products                  Gloria Wang, Chief Medical Officer, Shanghai Sinobioway Sunterra Biotech, China</p>	<p>Challenges, opportunities and partnerships in the ASEAN pharma industry: A regulatory perspective                  Kum Cheun (KC) Wong, Head of Asia Pacific, Regulatory and Development Policy, Novartis, Singapore</p>	<p>Next generation sequencing and biomarkers for oncology studies: What is the future?</p>	11:50	<p><b>Biotech Pitch</b>                  George Kopsidas, Executive Director and Chief Scientific Officer, Immunexus, Australia</p>
					12:00	<p><b>Exhibition Visit &amp; Networking Lunch</b></p>
12:20	<p>Development of next generation tumor immunotherapy                  Wenzhi Tian, MD, Chairman, CEO, ImmuneOnco Biopharma, China</p>	<p>Gearing up for a clinic with CRISPR technology: New strategies                  Seok Joong Kim, Board Member, Director and Head of Business Development, Toolgen, South Korea</p>	<p>Digital intervention in streamlining regulatory publishing &amp; submission activities                  Handsome Ji, APAC publishing lead, Pfizer, China</p>	<p>Data Science at the Frontlines: How can we use Big Data to showcase pharma's value to stakeholders?                  Prabhuram Krishnan, South Asia Medical Director, Ipsen Pharma, Singapore</p>	13:00	<p><b>PANEL: The Greater China Opportunity: Capital raising &amp; partnerships</b>                  Moderator:                  Ed Rosen, Executive in Residence, Columbia Technology Ventures, USA</p> <p>Panellist(s):  <a href="#">Jeffry Wu</a>, Managing Director, Milestone Capital, China  <a href="#">Sean Cao</a>, Managing Director, C-Bridge Capital Partners LLC, USA  <a href="#">Xichen Lin</a>, Research Director, Search &amp; Evaluation, Novo Nordisk, China  <a href="#">Marietta Wu</a>, Managing Partner, Quan Capital, China</p>
12:40	<p>Next generation targeted agents and immuno-oncology therapies  <a href="#">Vivian Bian</a>, COO, <a href="#">BeiGene</a>, China</p>	<p>Transitioning from an US food to an Asian drug company: A case study in clinical development                  Judy Walker, Chief Medical Officer, Accera Pharma, Singapore</p>	<p>Stakeholder management in regulatory affairs: A case study (topic to be confirmed)                  Shweta Uppal, Head, Clinical, Medical, Regulatory, Quality and Pharmacovigilance, Novo Nordisk, Malaysia</p>	<p>Early stage cancer diagnostics in APAC: Key development and opportunities</p>		

					13:40	Biotech Pitch Hardy Chan, Chairman & President, Allianz Pharmascience, Taiwan*
					13:50	Biotech Pitch Reserved for National Health Technology Park (NHTP), China
13:00	Exhibition Visit & Networking Lunch				14:00	Biotech Pitch Reserved for Korea Health Industry Development Institute (KHIDI)
	COMBINATION THERAPIES	MULTI REGIONAL CLINICAL TRIALS (MRCT)	INNOVATIVE NEW DRUG REGISTRATION	PHARMA 4.0: PATIENT CENTRICITY	14:10	Biotech Pitch Reserved for National Health Technology Park (NHTP), China
14:20	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks	14:20	Biotech Pitch Ian Huen, CEO, Aptorum Group, Hong Kong, China
14:30	When two is better than one: Opportunities in combination therapies	Clinical trial capacity related to MRCT in Taiwan I-Ning Tang, Team Leader, Center of Consultation, Taiwan Center for Drug Evaluation	CAR-T therapy regulation requirement in China Crystal Sun, CEO Assistant & Director, Regulatory & Government Affairs, Fosun Kite Biotechnology, China	Using digital platforms and social media for better patient engagement	14:30	Biotech Pitch Maijing Liao, Senior Vice President, Head of Business Development and Portfolio Management, Harbour BioMed, China
					14:40	Biotech Pitch Reserved for National Health Technology Park (NHTP), China
14:50	Device-Drug combination: The next generation combination therapy	GCP and safety guidelines for biosimilars products Salah Uddin, Assistant Director, Directorate General of Drug Administration, Bangladesh	<b>PANEL:</b> Expedited review pathways in North East Asia and what it means for APAC stakeholders <ul style="list-style-type: none"> <li>Priority review and reform for new product launches in China</li> <li>Latest updates on Good registration management (GRM) and approval pathways in Japan, Korea, Taiwan</li> <li>Opportunities to expand to greater Asia and lessons for the rest of Asia</li> </ul>	Remote patient management solutions for better engagement Nathanael Faibis, CEO, Alodokter, Indonesia	14:50	<b>PANEL:</b> Southeast Asia Focus: Fostering homegrown innovation and biotech firms Moderator: <ul style="list-style-type: none"> <li>Shwen Gwee, General Manager, Digital Accelerator (Global Drug Development), Novartis, USA</li> </ul> Panellist(s): <ul style="list-style-type: none"> <li>Xiangqian Lin, Managing Partner, Esco Ventures, Singapore</li> <li>Charles Stacey, CEO, Accera Pharma, Singapore</li> <li>Anand Gautam, Head of External Science &amp; Innovation, Pfizer, Australia</li> <li>Vishal Doshi, CEO, AUM Biosciences, Singapore</li> <li>Yuliana Indriati, President Director, PT Kalbe Genexine, Indonesia</li> </ul>
15:10	When east meets west: Combining immunotherapy with traditional Chinese medicine as complementary treatments	International cooperation and considerations in Asia MRCT Reserved for CRO sponsor	Moderator: Huong Nguyen, Regulatory Affairs Director MSD, Vietnam*  Panellist(s): Handsome Ji, APAC publishing lead, Pfizer, China Finny Liu, PDR APAC Regulatory Policy Lead, Roche, Singapore*	Virtual Reality for patient care and engagement Raghu Bathina, CEO, Celes Care, Founder, Future World Studios, India		

	IMMUNOTHERAPY BEYOND ONCOLOGY	MRCT ADOPTION & IMPLICATIONS	COMPLIANCE	PHARMA 4.0: DIGITAL THERAPEUTICS		
					15:30	Biotech Pitch Wenzhi Tian, MD, Chairman, CEO, ImmuneOnco Biopharma, China
15:30	Beyond T-cell I-O: Antiviral immunotherapy Victor Li, CEO, LionTCR, Singapore Antonio Bertoletti, Co-Founder, LionTCR, Singapore	<b>PANEL: MRCT in Southern and Southeast Asia: Implications &amp; opportunities</b> <ul style="list-style-type: none"> <li>Accounting regional differences in stepwise expansions</li> <li>Selection of suitable geographical regions</li> <li>How do South East Asia companies tap on MRCT opportunities in their near future strategies</li> </ul>	The role of pharmacovigilance in ensuring health product safety Mario Bertazzoli, Director, Group Head of Drug Safety, Helsinn Healthcare, Switzerland	Complement or replacement? Envisioning the future of digital therapeutics David Benshoof Klein, CEO and Founder, Click Therapeutics, USA	15:40	Biotech Pitch James Garner, CEO, Kazia Therapeutics, Australia
					15:50	Biotech Pitch Qin Gang, President, GeneQuantum Healthcare (Suzhou), China*
15:50	Immunotherapy in treating degenerative and metabolic diseases William D Milligan, SVP CD BD, Steminent Biotherapeutics, Taiwan*	Panellist(s): Arani Chatterjee, Senior Vice President, Clinical Research, Aurobindo, India Pei Yin Tan, Director, Asia Clinical Operations, Medicine Development Center, Eisai Clinical Research, Singapore	Quality Management System of CAR-T cell therapy Sam Shen, QA Director, Fosun Kite Biotechnology Co.,Ltd., China	Choosing the right business model for digital therapeutics	16:00	Biotech Pitch TS Balganes, President, Ganga Gen, India
					16:10	Biotech Pitch Simon Huang, EVP, Metagone, Taiwan*
16:10	Applying precision and immunotherapy to prevent infectious diseases		New compliance rules and what companies need to consider	Using real world data in digital intervention	16:20	Biotech Pitch
					16:30	Biotech Pitch
16:30	End of Phar-East 2019					



## EARLY CONFIRMED SPONSORS & EXHIBITORS

### SPONSOR



### EXHIBITORS



## SUPPORTING PARTNERS & ASSOCIATIONS

